Effect of L-carnitine in autism
Phase 3
- Conditions
- Autism.Autistic disorder
- Registration Number
- IRCT20190129042536N1
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
3 to 16 years old
IQ level above severe mental retardation
autism diagnosed based on DSM 5
Exclusion Criteria
Schizophrenia and psychotic disorders
History of drug or alcohol abuse
History of tardive dyskinesia
Neuroleptic drugs use or any psychotic medical treatment in the past 6 months
Known cases of medical diseases such as diabetes, respiratory diseases and asthma, renal diseases, hematologic disorders and...
Having aneurism or hematoma
Severe mental retardation
Taking anticonvulsant or antihypertensive drugs
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Behavioral symptoms, cognitive, social and physical health. Timepoint: Baseline, 4th week, 8th week. Method of measurement: ABC Questionnaire.
- Secondary Outcome Measures
Name Time Method Extrapyramidal symptoms. Timepoint: Baseline, 4th week, 8th week. Method of measurement: ESRS Questionnaire.